EUDA Health expands into T-cell immunotherapy

EUDA Health (EUDA) announced that it has secured distribution rights for T-cell immunotherapies in Malaysia developed by Shenzhen Inno Immune, a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in China. These T-cell immunotherapies are designed to restore and rebuild the body’s natural defenses. This marks EUDA’s second major step into advanced cell therapy this year, following its April 2025 distribution partnership with Guangdong Cell Biotech, a leader in autologous stem cell therapies in China. Together, these strategic actions reflect EUDA’s accelerated push into the regenerative and longevity medicine space, reinforcing its commitment to deliver science-driven, non-invasive solutions for aging and chronic conditions.